ASXL1

ASXL transcriptional regulator 1

Basic information

Region (hg38): 20:32358330-32439319

Links

ENSG00000171456NCBI:171023OMIM:612990HGNC:18318Uniprot:Q8IXJ9AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Bohring-Opitz syndrome (Definitive), mode of inheritance: AD
  • Bohring-Opitz syndrome (Definitive), mode of inheritance: AD
  • Bohring-Opitz syndrome (Strong), mode of inheritance: AD
  • Bohring-Opitz syndrome (Strong), mode of inheritance: AD
  • Bohring-Opitz syndrome (Strong), mode of inheritance: AD
  • Bohring-Opitz syndrome (Supportive), mode of inheritance: AD
  • Bohring-Opitz syndrome (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Bohring-Opitz syndromeADGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingCraniofacial; Dermatologic; Musculoskeletal; Neurologic21706002; 22419483

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the ASXL1 gene.

  • not provided (46 variants)
  • Bohring-Opitz syndrome (27 variants)
  • Inborn genetic diseases (8 variants)
  • ASXL1-related disorder (2 variants)
  • Myelodysplastic syndrome (2 variants)
  • Deficiency of iodide peroxidase (1 variants)
  • 10 conditions (1 variants)
  • dystrophia;Developmental delay (1 variants)
  • Spinocerebellar ataxia 45 (1 variants)
  • Myelodysplasia (1 variants)
  • Autosomal recessive limb-girdle muscular dystrophy (1 variants)
  • Rubinstein Taybi like syndrome (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the ASXL1 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
4
clinvar
194
clinvar
14
clinvar
212
missense
1
clinvar
364
clinvar
90
clinvar
38
clinvar
493
nonsense
30
clinvar
7
clinvar
37
start loss
1
clinvar
1
frameshift
44
clinvar
16
clinvar
3
clinvar
63
inframe indel
8
clinvar
2
clinvar
10
splice donor/acceptor (+/-2bp)
2
clinvar
1
clinvar
3
splice region
6
16
22
non coding
5
clinvar
38
clinvar
17
clinvar
60
Total 76 25 385 324 69

Highest pathogenic variant AF is 0.0000263

Variants in ASXL1

This is a list of pathogenic ClinVar variants found in the ASXL1 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
20-32358494-C-T Likely benign (Nov 25, 2018)338062
20-32358685-A-ACCG Bohring-Opitz syndrome Conflicting classifications of pathogenicity (Jul 01, 2023)338072
20-32358753-TGCC-T ASXL1-related disorder Likely benign (Dec 21, 2023)3045967
20-32358772-A-G Benign (Dec 30, 2019)1266577
20-32358776-A-C Uncertain significance (Aug 10, 2020)1210912
20-32358788-CAGA-C Benign/Likely benign (Jul 01, 2024)1272899
20-32358793-G-A Likely benign (Aug 04, 2023)1970514
20-32358793-G-C Inborn genetic diseases Uncertain significance (Apr 24, 2024)3319348
20-32358804-A-G Inborn genetic diseases Uncertain significance (Jan 18, 2022)2271945
20-32358811-G-A Likely benign (Jul 19, 2023)2744904
20-32358816-C-T Uncertain significance (Oct 27, 2022)1716339
20-32358823-C-T Likely benign (Mar 26, 2022)1991653
20-32358828-G-T Uncertain significance (Dec 03, 2021)1327369
20-32358829-C-T Likely benign (Dec 17, 2023)2821664
20-32358841-G-T Likely benign (Aug 04, 2023)1564198
20-32358843-C-T Likely benign (Dec 14, 2023)1915294
20-32358849-AGGGGGGCTCCGTGGGGCCCGGGGTGG-A Likely benign (May 12, 2022)1939360
20-32358849-A-AG Benign (Dec 13, 2023)1901363
20-32358851-G-A Bohring-Opitz syndrome;Myelodysplastic syndrome • Bohring-Opitz syndrome Benign/Likely benign (Jan 29, 2024)1168641
20-32358884-C-T Benign (Sep 23, 2019)1228443
20-32359043-G-GC Likely benign (Aug 21, 2019)1182355
20-32359302-A-C Likely benign (Jul 01, 2024)3257056
20-32359310-G-T ASXL1-related disorder Uncertain significance (Oct 03, 2023)2633954
20-32366367-C-T Likely benign (Oct 18, 2023)1616808
20-32366372-A-G Likely benign (Aug 12, 2022)1925456

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
ASXL1protein_codingprotein_codingENST00000375687 1380968
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
1.25e-140.9951256520961257480.000382
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.6367918430.9380.000050110006
Missense in Polyphen230297.050.774293532
Synonymous-0.4163493391.030.00002123221
Loss of Function2.773152.70.5890.00000322616

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004200.000420
Ashkenazi Jewish0.0005950.000595
East Asian0.0002290.000217
Finnish0.0001850.000185
European (Non-Finnish)0.0006010.000589
Middle Eastern0.0002290.000217
South Asian0.0001960.000131
Other0.0001650.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG). Acts as coactivator of RARA and RXRA through association with NCOA1. Acts as corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1). {ECO:0000250, ECO:0000269|PubMed:16606617, ECO:0000269|PubMed:20436459}.;
Disease
DISEASE: Bohring-Opitz syndrome (BOPS) [MIM:605039]: A syndrome characterized by severe intrauterine growth retardation, poor feeding, profound mental retardation, trigonocephaly, prominent metopic suture, exophthalmos, nevus flammeus of the face, upslanting palpebral fissures, hirsutism, and flexion of the elbows and wrists with deviation of the wrists and metacarpophalangeal joints. {ECO:0000269|PubMed:21706002}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Myelodysplastic syndrome (MDS) [MIM:614286]: A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS); chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. MDS is considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). {ECO:0000269|PubMed:19388938, ECO:0000269|PubMed:20182461}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Post-translational protein modification;Metabolism of proteins;UCH proteinases;Deubiquitination (Consensus)

Recessive Scores

pRec
0.0787

Intolerance Scores

loftool
0.955
rvis_EVS
0.17
rvis_percentile_EVS
65.77

Haploinsufficiency Scores

pHI
0.147
hipred
N
hipred_score
0.214
ghis
0.523

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.756

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Asxl1
Phenotype
cellular phenotype; homeostasis/metabolism phenotype; craniofacial phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; skeleton phenotype; immune system phenotype; vision/eye phenotype; digestive/alimentary phenotype; neoplasm; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); hematopoietic system phenotype; liver/biliary system phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Gene ontology

Biological process
cell morphogenesis;heart morphogenesis;transcription, DNA-templated;animal organ morphogenesis;protein deubiquitination;hemopoiesis;response to retinoic acid;negative regulation of peroxisome proliferator activated receptor signaling pathway;monoubiquitinated histone H2A deubiquitination;negative regulation of fat cell differentiation;positive regulation of transcription by RNA polymerase II;positive regulation of retinoic acid receptor signaling pathway;thymus development;bone marrow development;homeostasis of number of cells;lung saccule development
Cellular component
nuclear chromatin;nucleus;nucleoplasm;PR-DUB complex
Molecular function
DNA binding;chromatin binding;transcription coactivator activity;protein binding;retinoic acid receptor binding;peroxisome proliferator activated receptor binding;metal ion binding